Protein Design Labs Discontinues Daclizumab Development For Colitis; Asthma Is “Top Priority” Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is discontinuing development for ulcerative colitis in light of a Phase II study that failed to meet the primary efficacy endpoint: remission at week eight. Follow-on Phase II studies in asthma and multiple sclerosis are expected to begin by the first quarter of 2005.
You may also be interested in...
Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal
The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.
Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal
The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.
PDL/Roche Targeting Broad Zenapax Asthma Indication Under Development Deal
Roche signs on to PDL’s plans for daclizumab in development/marketing agreement for “asthma and related respiratory diseases.” PDL hopes initial asthma indication will be broader than that of Genentech/Novartis’ Xolair.